Official UK procurement notice
NP49119 Hepatitis C Medicines
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") (NHS & healthcare)·Consortium: 2 public authorities
What is being bought
Published requirement descriptionNo description was published on the notice. See the official documents.
CPV: Pharmaceutical products
The lotProcurement structure
single lot · no lot value publishedLot #1Lot 1 - This Framework Agreement is for the supply of medicines used in the treatment…
Lot 1 - This Framework Agreement is for the supply of medicines used in the treatment of Hepatitis C to NHS Scotland. This Lot is for the treatment cost per medicine.
Lot 2 - This Framework Agreement is for the supply of medicines used in the treatment of Hepatitis C to NHS Scotland. This Lot is for the treatment spend cap.
Procedure terms & legal framework
From the official record · publisher note attached- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Unspecified in notice
- Recurring procurement
- Unspecified in notice
- First published
- 4 Mar 2022, 10:49 GMT
- Last source update
- 13 Apr 2023, 08:39 BST
- FTS notice number
2023/S 000-010569- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-031e07Find a Tender
- Review procedure
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.
The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.
Publisher note: The estimated value(s) of the Framework Agreement referred to in Section V.2.4 (comprising two (2) Lots) cover(s) the twenty two (22) month contract duration and the twenty four (24) month extension period of the Framework Agreement. (SC Ref:728894)
How it was run
Official notice- Submission deadline
- —
Timeline
1 Jun 2019 → 13 Apr 2023 · 2 dates- Contract starts1 Jun 2019, 00:00 BST
- Notice published13 Apr 2023, 08:39 BST
Notice history
1 event · 2 releases on Find a Tender- Buyer details updated13 Apr 2023, 08:39 BST
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Abbvie Ltd, Gilead Sciences Ltd, Merck Sharpe and Dohme (UK) Limitedjoint award | £33,800,000 †same award published again · counted once | — | Awarded |
| Abbvie Ltd, Gilead Sciences Ltd, Merck Sharpe and Dohme (UK) Limitedjoint award | £51,787,422 † | — | Awarded |
Contracts
NP49119 Hepatitis C Medicines · Abbvie Ltd, Gilead Sciences Ltd, Merck Sharpe and Dohme (UK) Limited
- Signed
- 8 May 2019
- Value
- £33,800,000
- Period
- 1 Jun 2019 – 31 Mar 2023
- Status
- active
- Change This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector during the current Covid-19 pandemic and to maintain necessary supply due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015. Modification notice is advised at framework level and does not detail individual lots., Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee: This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector during the current Covid-19 pandemic and to maintain necessary supply due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015. Modification notice is advised at framework level and does not detail individual lots.
NP49119 Hepatitis C Medicines · Abbvie Ltd, Gilead Sciences Ltd, Merck Sharpe and Dohme (UK) Limited
- Signed
- 8 May 2019
- Value
- £51,787,422
- Period
- … – 31 Mar 2023
- Status
- active
- Change This modification effects an extension of the Framework Agreement duration from 01 April 2023 until 31 March 2024. The modification notice is advised at Framework Agreement level only and so it does not detail individual Lots. All Terms and Conditions of Contract remain in place., Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee: This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector during the Covid-19 pandemic and associated recovery, to maintain supply and remove unnecessary disruption from the Authority due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015.
Contracting authority & participating public bodies
2 public bodies on the noticeConsortium members and other public bodies
- NHS National Services ScotlandContracting authority
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Bidders & participating suppliers
4 commercial parties on the notice- AbbVie LtdAwarded supplier
- AbbVie LtdAwarded supplier
- Gilead Sciences LtdAwarded supplier
- Merck Sharp & Dohme UK LtdAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.